Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.

ABSTRACT:

Objectives

This study sought to determine the rate of chemotherapy-related cardiotoxicity and to estimate adherence to recommendations for cardiac monitoring among breast cancer patients treated with chemotherapy.

Background

Heart failure (HF) is a known complication associated with cancer therapies. Little is known regarding the rate of chemotherapy-related cardiotoxicity and adherence to recommendations for cardiac monitoring among chemotherapy-treated breast cancer patients.

Methods

Patients >18 years of age with a diagnosis of nonmetastatic invasive breast cancer between 2009 and 2014, treated with chemotherapy within 6 months of their diagnosis, were identified in the Truven Health MarketScan (IBM Watson Health, Cambridge, Massachusetts) database. HF, comorbiditi

SUBMITTER: Henry ML 

PROVIDER: S-EPMC6149535 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature